Abstract
Psychedelics a class of psychoactive compounds such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) are undergoing a scientific renaissance. Studies since 2020 have shown their therapeutic promise in mental health treatment. This Commentary synthesizes historical usage, current neuroscientific and clinical evidence, and explores ethical and regulatory frontiers for future medical integration. While showing efficacy in treatment-resistant depression, PTSD, and addiction, these substances require rigorous, ethically guided scientific validation.
Keywords
Psychedelics, Mental Health, Treatment, Psilocybin, Lysergic acid diethylamide, Dimethyltryptamine, Therapeutic benefits, Depression, Anxiety